Business Strategies
> Proprietary Pharmaceuticals
Proprietary
pharmaceuticals are often patent-protected or benefit from other
non-patent market exclusivities. These market exclusivities
generally provide proprietary products with the ability to maintain
their profitability for longer periods of time than generic
products. If a proprietary product has achieved physician and
customer loyalties, it will often remain profitable even following
the onset of generic competition, but generate lower profits
than it realized prior to generic competition.
Barr’s
proprietary pharmaceutical development activities are focused
in three main areas:
•
patent-protected proprietary products in late stages of development;
•
existing chemical compounds where the development of new forms
(liquid vs. tablets, different dosages or other drug delivery
systems, such as our proprietary, novel vaginal ring delivery
system) offer therapeutic or marketing advantages; and
•
new chemical entities in selected therapeutic categories,
including some that are marketed in other countries but not
currently sold in the United States.
Barr’s
proprietary development activities are currently focused on
expanding its portfolio of female healthcare products including
additional oral contraceptives and treatments for menopause/perimenopause
and endometriosis. The Company is also pursuing products in
urology, and is developing an oral vaccine product to prevent
Adenovirus (Types 4 & 7) infections. The Company continues
to identify other proprietary product candidates that further
expand its product offerings in these areas and is evaluating
additional therapeutic categories.
Product Guide 
